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Due to the growth number of infectious diseases, a huge demand of new antimicrobial agents are 
required. In this regard, Thiobarbituric acid (TBA) moieties were explored. As its name indicates, 
TBA is the sulfur version of the barbituric acid. The work in barbituric moieties dated long ago in 
1864 by Baeyer, when it was reported that these barbituric derivatives can be used as anesthetics, 
sedative or anticonvulsive agents.  
In the present work and taking advantage that TBA structure shows several points where diversity 
can be introduced, therefore several functionalities were introduced in the TBA analogues and 
their antimicrobial properties were studied in Gram-positive and Gram-negative bacteria. (Chapter 
1)  
These are the chemical modifications explored: i) N- substitution, where this site can be substituted 
with a symmetrical substituents; ii) reaction at C-5 position owing to the high acidity of the protons 
which includes acylation, acetylation, Schiff bases, Knoevenagel condensation thioamide and 
enamine formation.  
The antimicrobial activity screening for the synthesized compounds were against Gram-positive 
(S. aureus and B. subtilus) and Gram negative (E. coli and P. aeruginosa) bacteria. Among all 
thiobabituric derivatives synthesized, Boc-Phe-TBA showed a promising activity, which confirms 
that TBA could be an excellent scaffold when combined with N-protected amino acids for 
developing antimicrobial compounds. (Chapter 2) 
The characterization of 20 thiobarbituric derivatives was carried out in different spectroscopy 
techniques such as: Nuclear Magnetic Resonance (NMR), Ultra violet spectroscopy, Infra-Red 
spectroscopy and single X-ray crystallography. In NMR characterization the acetylation of TBA 
was the most interesting due to the fact that this type of compound have the tendency of forming 
Enol and Keto tautomerism. This was proved by NMR and also by theoretical calculation, and the 
results confirm that the 1H NMR for this compound (A01) showed resonance at 17.72 ppm (singlet) 
for OH. This indicate that the enol form is more stable than the keto form. In UV characterization 
due to the fact TBA derivatives are not known aromatic and yet they are UV active. Therefore the 
absorption of few TBA derivatives were study in different solvents hence these showed absorption 
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at maximum wavelength (max) in the range of 322 – 285 nm respectively. For IR characterization, 
these derivatives (A01, A02, A03, A04, A06, A10, A12, A13, A14 and A17) were evaluated, and 
showed absorption stretching frequency of thiocarbonyl (C=S) in three different ranges, 1395– 
1570 cm-1, 1260– 11420 cm-1  and 940 – 1140 cm-1 . For X- ray crystallography, crystals of A01, 
A02, A06, A13, A17 and A18 were obtained by hot recrystallization from ethanol and the 
intramolecular H-Bonding formation was observed in all cases, intermolecular H-bonding was 
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1. Antimicrobial agents and the need for new drugs  
A large demand for the development of new antimicrobial agents is still one of the major concern 
of medicinal chemists. This is due to the increasing number of infectious diseases that affect 
populations worldwide and in addition, the increase in the number of multi-drug-resistant bacteria, 
pose a serious threat to human health, therefore the incorporation of new antimicrobial agents will 
facilitate to fight and cure these infections.1-2  
The therapy to treat infections caused by bacteria were not advanced in the 1930s and majority of 
populations suffered from pneumonia, meningitis, typhoid fever, syphilis, tuberculosis, due to the 
living conditions and the lack of good antimicrobial agents3 When the antimicrobial agent was 
developed a new era started to control and treat these diseases.3 This antimicrobial therapy 
provided physicians with the ability to combat and cure certain diseases 
Our aim was to study the potential of thiobarbituric acid against Gram positive or Gram negative 
bacteria like E. coli, S. aureus, and P. aeruginosa .4  
2. Historical background of barbiturates derivatives. 
The barbiturates group contribute enormously in both biological and chemical fields.5 Although 
these compounds were officially discovered in 1864, by the German research chemist Baeyer, its 
history had the roots almost one century earlier. Barbituric acid started with the discovery of uric 
acid by Scheele in 17766 and in 1838 Liebig and Wohler oxidized uric acid with nitric acid and 
formed alloxantin.7 In 1845 Liebig’s student Schlieper synthesized hydurilic acid from uric acid 
while attempting to make alloxan,8 followed by oxidized alloxantin to obtain dilituric acid.9  
Baeyer oxidized hydurilic acid to obtain violuric acid which further oxidation yielded dilituric 
acid. Baeyer investigated these compounds and realized that all these compounds are related and 
belong to the barbituric acid series.10 Baeyer heated the mixture of hydurilic acid, nitric acid, and 
saturated bromine to obtain 5-dibromo barbituric, basically by performing the reaction of bromine 
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on violuric acid, dilituric acid, or hydurilic acid, obtained alloxanbromide also known as 5-
dibromo barbituric acid.9 He followed by synthesized barbituric acid from 5-dibromo barbituric 
acid by using two procedures; the first involved heating the reaction of dibromo barbituric acid 
with sodium amalgam (NaHg) and small amount of water and secondly by reacting dibromo 
barbituric acid with hydrogen iodide (HI) in water to obtain barbituric acid (first named 
Malonylurea) as shown in Figure 1.9  
 
Figure 1: Show the outline of the history of barbituric acid: (1) Schlieper 1845; (2) Sheele 1776 
                (3) Liebig Wohler 1838; (4) Baeyer 1863; (5) Baeyer 1864; (6) Grimaux 1979;   
                 (7) Schlieper; (8) Baeyer.9 
A few years later Mulder elucidated the correct structure of barbituric acid. Due to Baeyer’s 
procedure for synthesizing barbituric acid was long, subsequently, Grimaux developed in 1879 a 
straight forward procedure using malonic acid and urea in presence of phosphorous oxychloride, 
to obtained pure malonylurea (Barbituric acid).11 
Figure 2 showed general chemical structure of barbiturates, when the X position is substituted with 
oxygen it’s called “Barbiturates (C=O)” and “Thiobarbiturates” if X position is sulfur (C=S).  
3 
   
Figure 2: General and numbering of barbiturates 
3. The biological significance of (Thio) barbituric acid (TBA/BA) 
In 1904, barbiturate was introduced clinically as a sedative-hypnotic agent by the company 
Farbweke Fr. Bayer .5 As definition sedative agent decrease tension, anxiety and calm beneficiary 
whereas a hypnotic agent produces drowsiness and facilitates the start of sleep.12  
Barbiturates are widely known drugs with activity at the central nervous system (CNS), especially 
as an anticonvulsant, anxiolytics, tranquilizers and sedatives-hypnotics.13 According to some 
literature it has been reported that these drugs inhibit neurotransmitter chemical (acetylcholine, 
norepinephrine, and glutamate) and the calcium absorption of nerve terminals.13 The following 
drugs were among the first barbiturate derivatives (Pentobarbital, Phenobarbital, Amobarbital, 
Secobarbital,) to show activities at CNS especially as sedative-hypnotics activity (Figure 3).5  
 
Figure 3: First barbiturate derivatives that showed sedative-hypnotics activities.5 
Owing to their hypnotic and sedative behavior, nowadays a large number of CNS depressant drugs 
are available in the market, the most known CNS depressant is Benzodiazepines based which were 
commercialized in the 1960s.14   
Although it can be found in the early literature some references to the synthesis of some thio 
derivatives of the BA structure, the first serious study of the synthesis and biological activity of 
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thiobarbiturate (TBA) dated back in 1935.  Thus, Tabern et al in 1935 synthesized TBA analogs 
and showed to be more active as hypnotics than the oxygen analogs (BA).15  
Similarly to BAs, TBAs can be used in addition as anesthetics, sedatives or anti-convulsive agents. 
Its mode of action is through its tendency to bind to specific regions of various receptors e.g. to 
GABA, nicotinic-acetylcholine (nAChR) or BK channel receptors which are all ligand-gated ion 
channels.16 The substituted by alkyl or aryl group at C5 atom increase the binding to the GABA 
receptors. Furthermore, these substitution increases lipid solubility and simplifies transport of BA 
and TBA towards their enzyme target.16 
The discovering of sedative-hypnotic property associated with these type of compounds has fueled 
the synthesis of thousands of mainly BA and TBA derivatives as well. Modifications explored the 
substitution of both hydrogen atoms attached to nitrogen and the fifth position present in the BA 
structure with alkyl and aryl group.9 These class of compounds rapidly became attractive to a 
medicinal chemist, as in addition of their original properties,17-19 they bear a wide range of other 
biological activities: anti-inflammatory,20 anti-diabetic,21 anticonvulsant,22 anti-HIV,23 
anticancer,24 antiangiogenic, antihypertensive,25 antifungal, antibacterial,26 antimicrobial.27  
 
Although there are no commercially drugs based on TBA, these compounds are reported to exhibit 
better biological potency than BA.28 This can be due to the presence of the carbon-sulfur bond 
(C=S).29 The reason for higher biological activity behavior of TBA derivatives than BA derivatives 
is due to their better lipid solubility and better hydrogen bond acceptors. This last property 
simplifies binding to the enzyme receptors. 16 The oxygen and sulfur atoms in C=O and C=S group 
show differences in their physicochemical and biological properties due to the greater bulk and 
polarization of the sulfur atom and its decreased electronegativity.30 
A study on quantitative-structure-activity-relationship (QSAR) of molecules responsible for 
anesthetic activity reports that electronic factor is more important for biological activity than 
geometrical factors.31 The fact that TBA scaffold has not been broadly exploited in term of their 
biological activity, this gives us an opportunity to explore this core structure for their bioactivity.32  
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4. Antimicrobial activity  
Medicinal chemists researched for years to find drugs to substitute the ones that developed 
bacterial resistance. In literature, the TBA derivatives have been explored for antimicrobial activity 
associated with structure change at position N1, N3, C2 and C5 (Figure 2).14  
The target antibacterial potential studies of all synthesis were in Gram-positive and Gram-negative 
bacteria, particularly B. cereus, S. aureus, E. Coli, K. pneumonia, P. aeriginosa, and S. enterica.14 
In 2016, Dhorajiya et al. reported the MIC values of the chalcones of TBA group and BA group 
with former showing good potency towards P. aeruginosa whereas in case of E. coli the chalcones 
of BA are potent than the chalcones of TBA.32  
In 2009, Yan et al. investigated a series of 5-benzylidene BA and TBA derivatives followed by 
their evaluation to study inhibitory effects on the diphenolase activity of mushroom tyrosine and 
their antibacterial activities against Gram-positive and Gram-negative bacteria. The investigation 
was conducted and the outcome showed that most compounds had potential tyrosinase inhibitory 
activities, whereby the inhibitory effects of 5-benzylidene TBA on tyrosinase were of similar 
potency  (with an IC50 value of 14.49 µM) with 5-benzylidene BA (with an IC50 value of 13.98 
µM)  (Figure 5). 
 
Figure 5: 5-benzylidene BA and 5-benzylidene TBA. 
In the case of antibacterial activities, Yan et al. reported that all the synthesized 5-benzylidene 
TBA derivatives showed no antibacterial activities in vitro against S. epidermidis, S. Albus, B. 
ceres, E. coli, and P. aeruginosa, but comparing 5-benzylidene TBA, 2A, 2B and 2C with 5-
benzylidene BA derivatives 1A, 1B, and 1C, this showed thiobarbiturates 2A, 2B and 2C exhibited 
antimicrobial activities against S. aureus with the minimum inhibitory concentration (MIC) value 
6 
of 3.1, 3.1 and 6.25 µg/mL respectively, whereas BA derivatives exhibit no antimicrobial 
activities, supporting the fact that TBA derivatives are more bioactive than BA derivatives.28 
 
Figure 6: Compared TBA and BA that showed bio-activities against S.aureus. 
5. Synthesis of thiobarbiturates (TBA) derivatives 
As mentioned earlier, several attempts were made to synthesize barbiturates moieties, in 1879, 
Grimaux developed a straight forward procedure using malonic acid and urea, by mixing them in 




Figure 7: First straight forwards procedure developed for barbituric acid. 
A develop an alternative procedure to synthesize (thio)barbituric acid, was conducted  using 
(thio)urea, malonic acid in the presence of acetyl chloride under reflux condition (Figure 8).34 
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Figure 8: Alternative procedure developed for barbituric acid. 
 
Since the purpose of the project was to explore thiobarbituric acid (TBA) as a scaffold for the 
development of new antibacterial agents, and there are two sites which can be explored. All the 
compounds synthesized showed N-substitution to avoid antianxiety properties.17 In this regard, 
both “N” were substituted symmetrically, Secondly, C-5 position of TBA structure, since the 
proton at C-5 position is highly acidic therefore various reactions can be conducted at this position 
including acylation, acetylation, Schiff bases, Knoevenagel condensation and thioamide reactions, 
which has been explained below. 
5.1. Synthesis of N-Substituted thiobarbituric derivatives. 
The synthesis of N-substituted TBA derivative is conducted by condensation of an isothiocyanate 
with the corresponding amine to obtained symmetrical thiourea, follow by reacting the thiourea 
with malonic acid and acetyl chloride under reflux condition to afford respective N-substituted 
TBA derivative.34 
 




5.2. Schiff base reaction  
Schiff bases have been known since the middle of 19th century,35 since the study started in 1931 
with Pfeiff.36 A Schiff base is formation of imine by a reaction whereby C=O group of an aldehyde 
or ketone is replaced by carbon-nitrogen double bond (C=N-R3) group with nitrogen atom 
connected to an aryl or alkyl group, with a general formula R1R2C=NR3, where R3 is preferably a 
phenyl or alkyl group (leads to stable imine) than an aryl group (leads to unstable imine).37 The 
formation of the Schiff base is conducted by condensation of an aldehyde or ketone with a primary 
amine. The reaction is achieved with a nucleophilic attack of nitrogen from amine towards the 
carbonyl carbon to give the imine product or Schiff base, it generally takes place under acidic or 
basic catalyst, Scheme 2.38  
 
Figure 10: General formula of Schiff base. 
 
 
Scheme 2: Synthesis of Schiff base  
Schiff bases are widely used as pigment and dyes, catalysts, intermediates in organic synthesis, 
and as polymer stabilizers,37 and in addition, they are known for their broad range of biological 
activities, including antifungal, antibacterial, antimalarial, antiproliferative, anti-inflammatory, 
antiviral, and antipyretic properties.39-40 According to literature, in the case of the antibacterial, 
Schiff bases are known to interact with the lipopolysaccharides present in the outer membrane of 
bacteria to enhance the membrane permeability of bacteria.41 
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In 2012, Kalaivani, et al., compared the biological activities of Schiff base compounds A and B 
(Figure 9) with the standard reference Ciprofloxacin, the results indicate that some of the Schiff 
bases exhibit microbial activity against S. epidermis and E. coli.42 
 
Figure 9: Schiff base compounds A and B.42 
Due to the known properties of Schiff bases are as antimicrobials,37 they could be an excellent 
platform and therefore Schiff base derivatives of TBA were synthesized. 
 
5.3. Knoevenagel condensation reaction. 
Knoevenagel condensation is a reaction between active methylene derivative with a carbonyl 
compound in presence of base resulting in the formation of an olefin, C=C bond formation, 
developed in 1890 by Emil Knoevenagel (Scheme 3).43-45 
 
Scheme 3: Knoevenagel condensation reaction 
The role of the base is to abstract the acidic proton from the active methylene compound and the 
most common base used is pyridine, but there are reports where Knoevenagel condensation 
reaction was carried out in absence of a base. In 2001, Jursic et al. reported the Knoevenagel 
condensation between α, a β-conjugated aldehyde with barbituric acid in methanol (Scheme 4).29 
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Scheme 4: Several products of the Knoevenagel condensation products with barbituric acid as a 
source of ‘active’ methylene group.29 
Due to the presence of the activated methylene compounds,46 the primary unsaturated product may 
undergo Michael addition reaction, resulting in bis compounds. Michael addition reaction is a 
conjugate addition of a carbanion or other nucleophile (Michael donor) to an α, β-unsaturated 
carbonyl compound (Michael acceptor) as shown in Figure 10.47, 46  
 
Figure 10: General Michael addition reaction 
In Figure 10, the R1 and R2 are electron-withdrawing groups (acyl and cyano) increasing the acidic 
of hydrogen, and R3 is a ketone (enone), or a nitro group.
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The Knoevenagel condensation in case of TBA and aldehyde usually undergo Michael addition 
depending upon the substituents present on aldehyde.29, 49, 50 In 1999, Coe et al., reported the 
formation of Michael adduct, when reacted 1,3-diethyl-2-thiobarbituric acid with benzaldehyde 
derivatives with substituent at meta, ortho and para position,49 it was observed that reactivity 
towards Michael addition increases due to the presence of electron withdrawing substituents (such 
as –CN, or –NO2) when the molecule becomes more planar.51 
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Figure 11: Formation of Michael addition adducts 
In 2003, Jursic et al., reported whereby a reaction underwent a Michael addition reaction after 
Knoevenagel condensation reaction, involving a second nucleophilic addition of BA to α, β-
unsaturated carbonyl compounds and this can only be accomplished with the enol form of BA with 
a strong acid catalyst (Figure 12).52  
Figure 12: Knoevenagel condensation reaction followed by Michael addition reaction.52 
5.4. Acylation reaction 
Acylation reaction commonly refers to the introduction of an acyl group (R-C=O) to a molecule, 
where R is an alkyl group (aliphatic or alicyclic); the compound that provides the acyl group in 
acylation reaction is called “acylating agent”.53  
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Figure 13: General structure Acyl group. 
An acylation of BA at position C5 has been reported to have various biological potency. In this 
regard, Sakai et al. in 2002 reported library of acylation reactions using barbituric acid along with 
various acyl groups. The synthesis involved condensation reaction of barbituric acid derivatives 
represented by structure A below (Figure 14) and an acylation agent (B) such as acyl halides, acids 
anhydride, carboxylic acids, etc., in presence of a tertiary amine like triethylamine, 
diisopropylamine and N-methyl pyrrolidine.54 
 
Figure 14: General Acylation reaction of barbituric acid derivatives 
5.5. Thioamide synthesis reaction  
Thioamides (general structure: R1-CS-NR2R3 where R1, R2, and R3 are an aliphatic or aromatic 
group as shown in Figure 15) are functional groups for the preparation of a number of biological 
relevant heterocycles scaffolds.55 Some thioamides are known as plant protection agents or 
drugs,56 others are used as ligands in coordination chemistry.56 The first method for thioamide 
synthesis was introduced in 1878 by Hoffman which involved thionation of amides by phosphorus 




Figure 15: General structure of thioamide 
However, in 1988, Jagodzinski et al. developed a direct synthesis of thioamides by reacting 
aromatic isothiocyanate with substituted benzenes and phenol in a nitromethane solution of 
aluminum chloride (Figure 16).58 
 
Figure 16: Thioamide compound formation. 
The chemical and physical properties of thioamides are determined by the two active centers, one 
of them is associated with the nitrogen atom carrying a lone pair of the electron, and the other one 
is localized on the thiocarbonyl group.56  
In the literature, Pancechowska-ksepko et al, 2008 reported some piperazine derivatives contains 
thioamides group that show some biological activity. These compound were studied against 
anaerobic bacteria of Gram-positive and Gram-negative, the minimal inhibitory concentration for 
these compounds A, B, C, and D were compared with the MIC of standard Metronidazole at low 
concentrations 6.2-12.5 µg/mL.59 The derivatives studied showed distinguished activity towards 
the anaerobic bacteria but the maximum activity was exhibited by the compounds D.59 
 
Figure 20: Piperazine derivatives with thioamides group.59  
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6. Spectroscopic characterization  
Characterization of compounds to be used in a medicinal chemistry program should be conducted 
carefully to assure their structure.  In this regard, TBA derivatives have been characterized using 
various spectroscopic techniques such as Nuclear Magnetic Resonance spectroscopy (NMR), 
Ultra-violet spectroscopy (UV), Infra-Red spectroscopy (IR), Single X-Ray Crystallography. 
Nuclear magnetic resonance (NMR) is the most important analytical spectroscopic technique 
which helps chemists to elucidate the structure of synthesized compounds, for the advancement of 
organic chemistry.60 It is based on the magnetic properties of the nuclei of atoms (such as Proton 
in case of 1H NMR and Carbon for 13C NMR).61 The acetylated thiobarbituric acid analogs at C5 
position are known to form the Keto-enol tautomerism, which can be elucidated well by 
temperature dependent NMR analysis in different solvents.62 It has been shown by our research 
group earlier that enol form is more stable than keto derivative in case of acetylated barbituric 
acid.62  
Another analytical tool, Ultraviolet spectroscopy which helps in determining the bonding patterns 
by using electron transition, is defined as the measurement of the attenuation of a beam of light 
after it passes through a sample or after reflection from the sample.63 Most organic compounds 
have a different unsaturated functional group (alkene, aromatic compound, a compound with a 
carbonyl group, etc.) and UV-spectroscopy is used to detect the wavelength of these unsaturated 
functional group. The thiobarbituric derivatives are non-aromatic structurally but absorb UV on 
the TLC plate. This gives us the reason to study more and test their UV-absorption in different 
solvents (such as acetonitrile, ethanol, and dichloromethane).  
Infra-Red (IR) spectroscopy helps in determining a functional group of compounds by stretching 
and bending vibrations of each bond in the molecule and report the absorption bands using 
wavenumbers.63 It helps in the detection of specific functional groups as they are present as a 
characteristic band in the IR spectrum.  
X-ray crystallography is a technique for determining the three-dimensional structure of the 
molecules in space.64 This helps in better understanding of the derivatives structure along with the 
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presence of hydrogen bond donors and acceptors which can provide an insight into the explanation 
of biological activity. 
Bearing all these in mind, here we explored TBA as a scaffold for the development of new 
antibacterial agents followed by their complete characterization using the above-explained 
spectroscopic techniques. 
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Abstract Owing to their wide application in pharmaceutical industry, thiobarbituric acid (TBA) 
derivatives are also known to possess applications in engineering and material sciences.  20 TBA 
derivatives with diversity at position “N” and at “C-5” through acylation, Schiff base formation, 
Knoevenagel condensation, thioamide, and enamine formation were studied.  The absolute 
configuration for six derivatives was confirmed by single X-ray crystallography which indicates the 
formation of intramolecular H-bonding in all cases (A01, A02, A06, A13, A17, and A18) and also 
intermolecular H-bonding for A17. In A13 presence of two intramolecular bonding was observed. The 
stabilization of enol over keto form was confirmed using Gaussian09 program package. In order to 
convert the keto form to the enol, an energy barrier of 55.05 kcal/mol needs to be overcome as confirmed 
by transition state calculations. 
Keywords: Thiobarbituric acid; X-ray crystallography; UV spectroscopy; IR spectroscopy; 
DFT calculations; Transition state.  
1. Introduction 
A prerequisite for rational drug design and structure-based functional studies is the accurate knowledge 
about the molecular structure which is derived solely by X-ray crystallography (Aitipamula & Vangala, 
2017, Deschamps, 2008, Zheng et al., 2014). It is the most exhaustive technique available for 
determining 3-dimensional structure with correct configuration of the molecule at the atomic level. As 
structure and function are related, configuration plays a critical property in biological systems as 
changes in this may alter the response of the biologic system (Mason, 1983). Compounds containing 
BA/TBA moiety (Figure 1) plays a vital role as antianxiety agents in the central nervous system by 
binding to the γ-aminobutyric acid (GABA) receptor (Kapoor et al., 2016, Ahluwalia & Aggarwal, 
1996).  
 
Figure 1 The general structure of BA and TBA 
 
Thiobarbituric acid (TBA) derivatives are widely used as privileged structures for a broad range of 
biological activity including antiepileptic, anticancer, antioxidant, anticonvulsant, immuno-modulatory, 
gelatinase inhibiting, HIV integrase inhibiting, antifungal, antiviral, tyrosinase inhibiting, anti-
inflammatory and antidiabetic effects (Agarwal et al., 2006, Singh et al., 2009, Khan et al., 2008, Jursic 
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& Neumann, 2001, Jursic et al., 2003, Wang et al., 2011, Rajamaki et al., 2009, Lee et al., 2011, Chen 
et al., 2014, Penthala et al., 2013). The bioactivity, however, differs from molecule to molecule 
depending on the tautomerization and the nature of the substituents (Chierotti et al., 2010, Demeunynck 
et al., 2006). Apart from its importance in the pharmaceutical industry, TBA derivatives are also known 
to possess, non linear properties (NLO), corrosion inhibition properties, application in analytical 
chemistry and are suitable for crystal engineering materials possessing specific, programmed properties 
due to their property of possessing both hydrogen bond donors and acceptors (Ivanova & Spiteller, 
2010, Özcan et al., 2008, Roux et al., 2012).  
Protons at position C-5 in TBA are highly acidic and hence undergo various reactions, including 
acylation and Knoevenagel condensation, among others (Faidallah & Khan, 2012). Substitution at C-5 
increases lipophilicity and hence facilitates the transport of BA and TBA analogs towards their enzyme 
targets (Ahluwalia & Aggarwal, 1996). In view of the significance of TBA derivatives, we became 
interested in synthesizing new TBA derivatives with several C-5 substitutions including amino acids-




All reagents and solvents were purchased from commercial suppliers and were used without further 
purification unless otherwise stated. Fourier transform infrared spectroscopy (FTIR) spectra were 
recorded on Bruker-ALPHA Spectrophotometer in the spectral range 400-4000 cm-1. The electronic 
spectra of the studied compounds (1 mg in 50 mL solvent) were measured using 3600 Series UV-
Spectrophotometer in different solvents such as acetonitrile, ethanol, and dichloromethane. NMR 
spectra (1H NMR and 13C NMR) were recorded on a Bruker AVANCE III 400 MHz spectrometer. 
Chemical shift values are expressed in parts per million (ppm). Analytical HPLC was performed on 
Agilent 1100 system using Phenomena C18 column (3 µm, 4.6 × 50 mm), and Chemstation software 
was used for data processing over a 5-95 % gradient of CH3CN (0.1% TFA)/ H2O (0.1% TFA) over 15 
min, flow rate: 1.0 mL/min, detection at 220 nm. High-resolution mass spectrometry (HRMS) was 
performed using a Bruker ESI-QTOF mass spectrometer in positive-ion mode. 
2.2. Synthesis of derivatives 
The derivatives (A01-A20) had been synthesized as reported by our group earlier (Sharma et al., 
2018). Further characterization: 
5-acetyl-1,3-diethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A01) 
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Pale white solid. 82% yield, mp = 40-42°C; HPLC tR = 11.9 min; max = 316 nm; IR (cm-1): 1231 (C=S), 
1685 (C=O); 1H NMR (400 MHz, DMSOd6): 1.18 (t, J = 7 Hz, -CH3), 2.65 (s, -CH3), 4.40 (q, J = 7 Hz, 
-CH2); 13C NMR (100 MHz, DMSOd6): 11.8, 24.5, 42.5, 78.9, 97.4, 177.1, 197.3. HRMS: m/z: calcd. 
for C10H14N2O3S: 243.0798 [M+H]+; found: 243.0811. 
1,3-diethyl-5-propionyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A02) 
Pale white solid. 56% yield, mp = 74-75°C; HPLC tR = 12.9 min; IR (cm-1): 1227 (C=S), 1680 (C=O); 
1H NMR (400 MHz, DMSOd6): 1.14 (t, J = 7.4 Hz, -CH3), 1.19 (t, J = 7.0 Hz, -CH3), 3.11 (q, J = 7.4 
Hz, -CH2), 4.41 (q, J = 7.0 Hz, -CH2); 13C NMR (100 MHz, DMSOd6): 8.9, 11.8, 30.7, 42.6, 96.6, 
171.6, 177.0, 201.4. HRMS: m/z: calcd. for C11H16N2O3S: 257.0954 [M+H]+; found: 257.0966.  
5-benzoyl-1,3-diethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A03) 
Pale white solid. 36% yield, mp = 92-93°C; HPLC tR = 13.1 min; IR (cm-1): 1287 (C=S), 1675 (C=O); 
1H NMR (400 MHz, DMSOd6): 1.18 (t, J = 7.0 Hz, -CH3), 4.39 (q, J = 7.0 Hz, -CH2), 7.4-7.6 (m, ArH); 
13C NMR (100 MHz, DMSOd6): 12.1, 42.3, 96.3, 127.6, 128.4, 131.4, 137.1, 161.6, 167.3, 177.0, 192.3. 
HRMS: m/z: calcd. for C11H16N2O3S: 305.0954 [M+H]+; found: 305.0957. 
tert-butyl (1-(1,3-diethyl-4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)-1-oxo-3-phenylpropan-2-
yl)carbamate (A04) 
Pale pink solid. 94% yield, mp = 130-131°C; HPLC tR = 14.4 min; max = 322 nm; IR (cm-1): 1164 
(C=S), 1682 (C=O) 3359 (N-H); 1H NMR (400 MHz, DMSOd6): 1.18 (t, J = 7.2 Hz, -CH3), 1.28 (s, -
CH3), 3.09-3.12 (m, -CH2), 4.44 (q, J = 7.2 Hz, -CH2), 5.52 (t, J = 7.8, -CH), 7.16 (d, J = 7.3 Hz, -NH), 
7.21-7.33 (m, ArH); 13C NMR (100 MHz, DMSOd6): 12.4, 18.8, 28.1, 45.7, 60.2, 69.9, 71.9, 125.7, 
127.7, 129.3, 138.9, 155.1, 177.1, 183.8, 216.1. HRMS: m/z: calcd. for C11H16N2O3S: 448.1900 
[M+H]+; found: 448.1901. 
1,3-diethyl-5-phenylalanyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A05) 
Pale pink gum. 98% yield; HPLC tR = 7.6 min; max = 308 nm; 1H NMR (400 MHz, DMSOd6): 1.15 (t, 
J = 6.8 Hz, -CH3), 3.08-3.12 (m, -CH2), 4.20 (t, J = 5.5 Hz, -CH), 4.40 (q, J = 6.8 Hz, -CH2), 7.23-7.30 
(m, ArH), 7.72 (bs, -NH2); 13C NMR (100 MHz, DMSOd6): 12.5, 41.5, 53.1, 58.5, 95.0, 128.4, 128.6, 
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Dark pink solid. 92% yield, mp = 100-101°C; HPLC tR = 14.1 min; max = 320 nm; IR (cm-1): 1105 
(C=S), 1623 (C=O) 3369 (N-H); 1H NMR (400 MHz, DMSOd6): 0.81 (d, J = 6.8 Hz, -CH3), 1.18 (t, J 
= 6.6 Hz, -CH3), 1.37 (s, -CH3), 3.06-3.11 (m, -CH), 3.80 (s, -CH), 4.41 (q, J = 6.8 Hz, -CH2), 5.52 (d, 
J = 7.3 Hz, -CH), 6.87 (s, NH); 13C NMR (100 MHz, DMSOd6): 11.9, 28.1, 30.1, 42.6, 52.1, 58.9, 78.1, 
139.1, 155.6, 168.7, 176.8, 199.5. HRMS: m/z: calcd. for C11H16N2O3S: 400.1901 [M+H]+; found: 
400.1884. 
1,3-diethyl-2-thioxo-5-valyldihydropyrimidine-4,6(1H,5H)-dione (A07) 
Dark pink gum. 97% yield; HPLC tR = 6.6 min; 1H NMR (400 MHz, DMSOd6): 0.76 (d , J = 7 Hz, -
CH3), 1.2 (t, J = 7 Hz, -CH3), 2.16 (m, -CH), 3.10 (m, -CH), 4.37 (q, J = 7 Hz, -CH2), 4.96 (d, J = 8.5 
Hz, -CH), 7.66 (bs, NH2); 13C NMR (100 MHz, DMSOd6): 12.5, 15.8, 19.6, 29.1, 41.5, 61.5, 160.1, 
176.7, 190.5. HRMS: m/z: calcd. for C11H16N2O3S: 300.1376 [M+H]+; found: 300.1377. 
(E)-1,3-diethyl-5-(1-((pyridin-2-ylmethyl)imino)ethyl)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione 
(A08) 
Pale yellow solid (gummy at room temperature). 86% yield; HPLC tR = 8.8 min; 1H NMR (400 MHz, 
CDCl3): 1.22 (t, J = 7.0 Hz, -CH3), 2.69 (s, -CH3), 4.49 (q, J = 7.0 Hz, -CH2), 4.75 (d, J = 5.6 Hz, -CH2), 
7.2-8.6 (m, ArH), 13.3 (s, -CH); 13C NMR (100 MHz, CDCl3): 11.4, 17.9, 41.8, 42.2, 48.2, 92.3, 120.4, 




White solid. 69% yield, mp = 98-100°C; HPLC tR = 12.6 min; 1H NMR (400 MHz, CDCl3): 1.21 (t, J 
= 6.9 Hz, -CH3), 2.10 (s, -OCH3), 2.66 (s, -CH2), 3.75 (s, -CH3), 4.47 (q, J = 7.0 Hz, -CH2), 6.84-7.15 
(m, ArH), 12.96 (s, -CH); 13C NMR (100 MHz, CDCl3): 11.4, 17.2, 41.8, 42.6, 46.8, 54.9, 113.7, 127.4, 
130.1, 152.1, 154.4, 167.4, 173.6 HRMS: m/z: calcd. for C11H16N2O3S: 362.1533 [M+H]+; found: 
362.1535. 
1,3-diethyl-5-(4-fluorobenzylidene)-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A10) 
Yellow solid. 70% yield, mp = 180-182°C; HPLC tR = 11.9 min; max = 287 nm, 361 nm; IR (cm-1): 
1108 (C=S), 1614 (C=O); 1H NMR (400 MHz, CDCl3): 1.30 (t, J = 7.0 Hz, -CH3), 4.59 (q, J = 7.0 Hz, 
-CH2), 7.00-7.04 (m, Ar-H), 13.86 (s, -CH); 13C NMR (100 MHz, CDCl3): 12.1, 45.2, 97.4, 115.2, 
115.4, 127.9, 128.0, 162.2, 163.7, 174.6. HRMS: m/z: calcd. for C11H16N2O3S: 307.0911 [M+H]+; 
found: 307.0908. 





Yellow solid. 74% yield, mp = 150-151°C; HPLC tR = 13.2 min; max = 284 nm, 366 nm; 1H NMR (400 
MHz, DMSOd6): 1.16 (t , J = 7.0 Hz, -CH3), 3.44 (m, -CH), 3.62 (s, -OCH3), 4.45 (q, J = 7.0 Hz, -CH2), 
6.10-6.26 (m, Ar-H), 8.10 (d, J = 6.6, -CH); 13C NMR (100 MHz, DMSOd6): 12.3, 18.5, 33.6, 42.8, 




Buff solid. 76% yield, mp = 163-165°C; HPLC tR = 12.2 min; max = 289 nm; IR (cm-1): 1108 (C=S), 
1611 (C=O);1H NMR (400 MHz, DMSOd6): 1.14 (t , J = 6.7 Hz, -CH3), 4.40 (q, J = 6.7 Hz, -CH2), 6.42 
(s, -CH), 7.51-8.41 (m, Ar-H); 13C NMR (100 MHz, DMSOd6): 12.1, 32.3, 42.8, 94.2, 118.9, 125.6, 
130.9, 143.4, 145.5, 149.3, 160.7, 174.4. HRMS: m/z: calcd. for C11H16N2O3S: 579.1326 [M+H]+; 
found: 579.1322. 
1,3-diethyl-4,6-dioxo-2-thioxo-N-(p-tolyl)hexahydropyrimidine-5-carbothioamide (A13) 
Pale yellow solid. 90% yield, mp = 132-133°C; HPLC tR = 15.6 min; max = 333 nm; IR (cm-1): 1105 
(C=S), 1645 (C=O);1H NMR (400 MHz, DMSOd6): 1.31 (t , J = 7.0 Hz, -CH3), 2.39 (s, -CH3), 4.58 (q, 
J = 7.0, -CH2), 7.31-7.39 (m, Ar-H), 13.9 (s, -NH); 13C NMR (100 MHz, DMSOd6): 11.6, 20.7, 43.8, 
91.7, 125.2, 129.5, 134.5, 137.0, 174.3, 184.9, 202.9. HRMS: m/z: calcd. for C11H16N2O3S: 350.0991 
[M+H]+; found: 350.0962. 
2-thioxo-1,3-di-p-tolyldihydropyrimidine-4,6(1H,5H)-dione (A14) 
Yellow solid. 92% yield, mp = 218-220°C; HPLC tR = 10.2 min; max = 241 nm, 286 nm; IR (cm-1): 
1339 (C=S), 1700 (C=O);1H NMR (400 MHz, DMSOd6): 2.27 (s, -CH3), 7.12 (d, J = 8.1 Hz Ar-H), 
7.33 (d, J = 8.1 Hz, Ar-H), 9.58 (s, -CH2,); 13C NMR (100 MHz, DMSOd6): 21.1, 40.6, 128.4, 129.5, 
136.6, 137.9, 169.3, 174.2. HRMS: m/z: calcd. for C11H16N2O3S: 325.1005 [M+H]+; found: 325.1025. 
5-acetyl-2-thioxo-1,3-di-p-tolyldihydropyrimidine-4,6(1H,5H)-dione (A15) 
Yellow solid. 45% yield, mp = 185-186°C; HPLC tR = 12.0 min; 1H NMR (400 MHz, DMSOd6): 2.34 
(s, -CH3), 2.65 (s, -CH3), 7.15 (d, J = 8.2 Hz Ar-H), 7.26 (d, J = 8.2 Hz, Ar-H); 13C NMR (100 MHz, 
DMSOd6): 20.7, 24.5, 98.2, 128.5, 129.5, 136.7, 137.6, 179.6, 196.3, 206.9. HRMS: m/z: calcd. for 
C11H16N2O3S: 366.1077 [M+H]+; found: 366.1100. 




Yellow solid. 57% yield, mp = 140-141°C; HPLC tR = 12.7 min; max = 318 nm; 1H NMR (400 MHz, 
DMSOd6): 1.14 (t, J = 7.4 Hz, -CH3), 2.33 (s, -CH3), 2.91 (q, J = 7.4 Hz, -CH2), 7.08 (d, J = 8.2 Hz, 
Ar-H), 7.20 (d, J = 8.2 Hz, Ar-H); 13C NMR (100 MHz, DMSOd6): 10.1, 20.7, 30.1, 63.4, 128.5, 129.5, 
137.6, 166.2, 170.6, 179.5, 187.6. HRMS: m/z: calcd. for C11H16N2O3S: 381.1290 [M+H]+; found: 
381.1267. 
5-(1-aminoethylidene)-1,3-diethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A17) 
Yellow solid. mp = 190-191°C; HPLC tR = 9.2 min; max = 320 nm; IR (cm-1): 1357 (C=S), 1613 (C=O) 
3295 (N-H); 1H NMR (400 MHz, DMSOd6): 1.14 (t, J = 7 Hz, -CH3), 2.53 (s, -CH3), 4.37 (q, J = 7 Hz, 
-CH2), 9.7 (s, -NH2), 11.1 (s, -NH2); 13C NMR (100 MHz, DMSOd6): 12.1, 24.3, 42.0, 91.2, 175.8, 
176.9, 197.3. HRMS: m/z: calcd. for C11H16N2O3S: 242.0958 [M+H]+; found: 242.0966. 
5-(1-aminopropylidene)-1,3-diethyl-2-thioxodihydropyrimidine-4,6(1H,5H)-dione (A18) 
Yellow solid. mp = 101-102°C; HPLC tR = 10.1 min; 1H NMR (400 MHz, DMSOd6): 1.15 (t, J = 7.3 
Hz, -CH3), 1.16 (t, J = 6.9 Hz, -CH3), 2.53 (q, J = 7.3 Hz, -CH3), 4.40 (q, J = 6.9 Hz, -CH2), 9.68 (s, -
NH2), 11.18 (s, -NH2); 13C NMR (100 MHz, DMSOd6): 12.2, 12.7, 29.2, 42.1, 90.3, 161.2, 176.9, 180.6. 
HRMS: m/z: calcd. for C11H16N2O3S: 256.1080 [M+H]+; found: 256.1096. 
5-(1-aminoethylidene)-2-thioxo-1,3-di-p-tolyldihydropyrimidine-4,6(1H,5H)-dione (A19) 
Yellow solid, mp = 198-200°C; HPLC tR = 9.9 min; 1H NMR (400 MHz, DMSOd6): 1.23 (s, -CH3), 
2.33 (s, -CH3), 7.07 (d, J = 8.2 Hz, Ar-H), 7.20 (d, J = 8.2 Hz, Ar-H), 9.69 (s, -NH2), 10.9 (s, -NH2); 
13C NMR (100 MHz, DMSOd6): 20.8, 23.4, 101.2, 129.8, 132.4, 136.2, 137.3, 162.8, 167.3, 172.5. 
HRMS: m/z: calcd. for C11H16N2O3S: 366.1282 [M+H]+; found: 366.1271. 
5-(1-aminopropylidene)-2-thioxo-1,3-di-p-tolyldihydropyrimidine-4,6(1H,5H)-dione (A20) 
Yellow solid, mp = 159-160°C; HPLC tR = 10.6 min; 1H NMR (400 MHz, DMSOd6): 1.14 (t, J = 7.4 
Hz, CH3), 2.33 (s, -CH3), 2.91 (q, J = 7.4 Hz, CH2), 7.08 (d, J = 8.2 Hz, Ar-H), 7.20 (d, J = 8.2 Hz, Ar-
H), 9.62 (s, -NH2), 10.97 (s, -NH2); 13C NMR (100 MHz, DMSOd6): 9.8, 20.7, 24.5, 98.2, 128.5, 129.5, 
136.7, 137.6, 162.4, 179.6, 196.3. HRMS: m/z: calcd. for C11H16N2O3S: 380.1436 [M+H]+; found: 
380.1427. 
2.3. Structure Determination  
All non-hydrogen atoms were first refined isotropically and then anisotropically with full-matrix least 
squares based on F2 using SHELXL (Sheldrick, 2015). All hydrogen atoms were positioned 
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geometrically, allowed to ride on their parent atoms, and refined isotropically. In A06, the hydrogen 
atom of the enol unit was found to be disordered over two positions between the enol and one of the 
carbonyl groups of the thiobarbituric ring. PART instructions were used to resolve the disorder and to 
achieve occupancy of 50% in the major component. Crystal data and structural refinement information 
are summarized in Table 2. 
Table 1 Crystallographic data and structural refinement details of A01, A02, A06, A13, and A18. 
 A01 A02 A06 A13 A17 A18 
Chemical 
formula 
C10H14N2O3S C11H16N2O3S C18H29N3O5S C16H19N3O2S2 C10H15N3O2S C11H17N3O2S 










































90, 90, 90 
V (Å3) 1125.51(6) 603.95(3) 1960.3(5) 1582.61(10) 2290.10(13) 1226.62(14) 
Z 4 2 4 4 8 4 
µ (mm−1) 0.28 0.27 0.20 0.35 0.27 0.26 
Crystal size 
(mm) 
0.29 × 0.23 × 
0.12 
0.19 × 0.14 
× 0.07 
0.33 × 0.25 × 
0.21 
0.19 × 0.12 × 
0.11 
0.19 × 0.13 × 
0.09 
0.25 × 0.11 × 
0.09 



















Rint 0.016 0.021 0.023 0.027 0.024 0.026 
(sin θ/λ)max (Å−1) 0.667 0.650 0.654 0.675 0.642 0.649 

















—  0.035(16)* 0.00(2)* — — -0.01(3)* 
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Δρmax, Δρmin (e 
Å−3) 
0.40, −0.19 0.25, −0.22 0.25, −0.18 0.38, −0.25 0.28, −0.27 0.31, −0.16 
*Flack x determined using 1256, 1743, and 1059 quotients [(I+)-(I-)]/[(I+)+(I-)] for A02, A06 and A18, 
respectively. 
2.4. Theoretical Calculations  
According to the above crystal structure, a crystal unit was selected as the initial structure, while DFT-
B3LYP/6-311G++(d,p) methods in Gaussian09 (Frisch et al., 2009) was used to optimize the structure 
of the title compound. No solvent corrections were made with these calculations. Vibration analysis 
showed that the optimized structure indeed represents a minimum on the potential energy surface (no 
negative eigenvalues). A four-membered ring transition state was calculated. The transition state was 
also confirmed using IRC (Gonzalez & Schlegel, 1989, 1990) calculations.  
3. Result and Discussion  
All the derivatives (Scheme 1) were synthesized earlier by our group (Sharma et al., 2018) and well 
characterized by spectroscopic techniques which will be discussed in the subsequent sections. 
 
Scheme 1: a) Anhydride/NaHCO3/H2O, overnight; b) Boc-amino acid, EDC, HOBt, DMAP, DCM, 16 
h; c) NH4Cl/EtOH, overnight; d) Amine/Conc HCl/EtOH, overnight; e) aldehyde/EtOH, 10 min; f) 
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Isothiocyanate, DIEA, DCM, overnight; g) TFA, 1 h; h) malonic acid and acetyl chloride, 40 °C, 12 h; 
i) Acetic acid/Propionic acid, few drop conc H2SO4, reflux 1 h. 
 
3.1. Synthesis and characterization 
All the derivatives were synthesized earlier by our group (Sharma et al., 2018) and were characterized 
by NMR followed by UV spectrometry using different solvents. Some of the derivatives (A01, A02, 
A03, A04, A06, A10, A12, A13, A14, and A17) were evaluated for IR spectroscopy and different 
absorption stretching frequencies were examined and compared with reported literature (Larkin, 2017). 
The absorption of thiocarbonyl (C=S) stretching frequency varies in three different ranges, 1395– 1570 
cm-1, 1260– 11420 cm-1  and 940 – 1140 cm-1 when attached with tertiary nitrogen and the absorption 
of C=S in all the spectra was found in range 1108-1357 cm-1 which is in agreement with reported 
literature (Pretsch et al., 2000). In A12 the absorption at 1377 cm-1 indicated the presence of a nitro 
group (NO2). The presence of stretching frequency at 1680 cm-1, 825 cm-1 and 1613 cm-1, 838 cm-1 in 
A01 and A17 respectively, indicates the presence of “substituted alkene”. A broad signal around 1541 
cm-1 indicates the enol “-OH”. A distinct signal at 3295 cm-1 in A17 further indicates the presence of a 
primary amine, clearly confirming the enamine formation.  
In A01, the C-5 proton in acetylated DETBA showed a signal at 17.72 ppm (singlet), which reflects the 
presence of OH, hence indicating that the enol form is more stable than the keto form. The enolization 
of the carbonyl group was also in excellent agreement with the observed 96.7 ppm for C-5 as shown by 
13C NMR. Furthermore, NMR for A17, A18, A19, and A20 revealed the shift of peaks during the 
conversion from enol to enamine. Of note, we detected an interesting feature in all enamine derivatives 
where the "NH2" proton showed two distinct peaks, one around 9.7 ppm and another at 11 ppm, clearly 
depicting different behavior of 2 protons in "-NH2".  
Given that the non-aromaticity of TBA, they absorb UV on the TLC plate and during the HPLC hence 
UV absorption of few derivatives was also studied using acetonitrile (ACN), ethanol and 
dichloromethane (DCM) as a solvent. 1,3-Diethyl-2-thiobarbituric acid (DETBA) showed max 
absorption at 285 nm. A01 showed absorption at a maximum (max) of 316 nm, whereas A04 and A12 
showed absorption at 322 nm and 289 nm respectively. However, similar results were obtained for A12 
in case of ethanol as a solvent but in case of DCM as solvent max was observed at 305 nm. Also 
derivative with an aryl substitution on "N", A14, absorbed at 286 nm. However, with further substitution 
at C-5 in A14 affording A16, shifts max to 318 nm. Comparison of A01 and A17 revealed UV 
absorption changes from 316 nm to 320 nm as the conversion from keto to enamine form occurred.  




Figure 2 UV spectra of some TBA derivatives 
In the case of A04,  max absorption was at 322 nm, and absorption shifted slightly to 308 nm after Boc 
removal in A05. A06 showed max absorption at 320 nm, a value that did not differ greatly from that of 
A04. UV-vis absorption was also studied for the Knoevenagel reaction (A10 and A11). Two max 
absorption peaks: one caused by DETBA and the other by the respective aldehyde were detected. For 
A10, max absorption peaks were at 287 nm and 361 nm, whereas for A11 they were at 284 nm and 366 
nm. The reaction of DETBA with p-tolyl isothiocyanate resulted in A13, which has a thioamide bond 
which showed a shift from 285 nm (in case of DETBA) to 333 nm. Furthermore, A14 showed two UV-
vis absorption peaks at 241 nm and 286 nm, which were caused by the presence of "tolyl", as well as a 
"thiobarbituric ring".  
3.2. Crystal structure descriptions of A01, A02, A06, A13, A17 and A18 
Colorless X-ray quality crystals of A01, A02, A06, A13, A17, and A18 were obtained by hot 
recrystallization from ethanol.  




Figure 3 ORTEP diagrams of compounds A01, A02, A06, A13, A17, and A18 drawn at 50% thermal 
ellipsoid probability. One of two molecules of compound A17 was omitted for clarity. 
Molecules in the asymmetric unit of these derivatives are shown in Figure 3. Each molecule consists of 
a DETBA ring with either an enol (in A01, A02, and A06), enamine (in A17 A18) or thioamide (in 
A13) moieties. The DETBA ring together with the various moieties was identified as planes that best 
describe the molecular conformations of A01, A02, A06, A13, A17, and A18. The DETBA, enol, 
enamine, and thioamide planes are denoted as PDETBA, PENOL, PENAMINE and PTHIOAMIDE, respectively, 
whilst the dihedral angles between corresponding planes are designated as PDETBA—PENOL, PDETBA—
PENAMINE or PDETBA—PTHIOAMIDE. The dihedral angles between the various planes and root mean square 
deviation (RMSD) of fitted atoms of DETBA are listed in Table 2. The six-membered DETBA ring did 
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not appear to be completely planar in any of the compounds since the RMSD values of fitted atoms of 
DETBA rings were all greater than zero. The RMSD of PDETBA increased as the carbon chain on the 
enol in A01 (0.0187) extended to A02 (0.0270). Interestingly, the presence of a bulky Boc-Val group 
to the enol in A06 significantly improved the planarity of the PDETBA over that observed in A01. 
However, the PDETBA—PENOL dihedral angle appeared to increase with the carbon chain length and steric 
demand of the enol moiety. Compound A17 is an enamine form of A01 and showed RMSD values 
(0.0465—0.544) higher than those of all the enol counterparts with PDETBA—PENAMINE dihedral angles 
ranging between 5.2(2) and 7.9(2)°. In contrast to enol derivatives A01 and A02, extending the carbon 
chain of the enamine forms of A01 and A02 led to a decrease in the RMSD of the DETBA ring from 
0.0465—0.0544 (in A17) to 0.0245 (in A18). Exchanging the enamine for a thioamide moiety in A13 
resulted in the smallest dihedral angle (PDETBA—PTHIOAMIDE = 0.2(2)°) observed in this series, with a 
PDETBA RMSD that was intermediate to that of the enol derivatives (Table 3). 
Table 2 RMSD values of fitted atoms of PDETBA and dihedral angles between PDETBA—PENOL, 
PDETBA—PENAMINE and PDETBA—PTHIOAMIDE observed in A01, A02, A06, A13, A17, and A18. 
Compound RMSD of fitted atoms of PDETBAa 
Dihedral angle 
[PDETBA—PENOLb/PENAMINEc/PTHIOAMIDEd]/ ° 
A01 0.0187 6.3(1) 
A02 0.0270 7.3(2) 
A06 0.0117 8.7(2) 






A18 0.0245 5.6(2) 
aAtoms used t define PDETBA: (A01) C3—C6—C7—C8—N1—N2; (A02) C4—C5—C9—N2—C8—
N1; (A06) C8—C3—C6—N2—N1—C7; (A13) C3—C4—C11—C14—N1—N3; (A17) C3—C9—
C10—C8—N3—N2; (A18) C3—C9—C10—C11—N1—N2 
b Atoms used to define PENOL: (A01) C9—C10—O3; (A02) C1—C2—C3—O3; (A06) C9—C10—O3 
c Atoms used to define PENAMINE: (A17) C6—C7—C8—N1; (A18) C6—C7—C8—N3 
d Atoms used to define PTHIOAMIDE: (A13) C5—N2—S2 
The bond distances and angles are comparable to related compounds (Coe et al., 1999, Asiri et al., 
2009, Galán et al., 2012, Bourhill et al., 1994). However, bond parameters of interest in compounds 
A01, A02, A06, A17, and A18 are summarized in Table 4. Compounds A01 and A02 displayed enolic 
properties, evidenced by a shorter Ccarbonyl—Ocarbonyl (1.247(2)—1.257(2) Å) bond distance than Cenol—
Oenol (1.309(2)—1.301(2) Å) which were comparable with that of the enamine forms, A17 and A18. 
Furthermore, the Cethylene—Cenol (1.398(2)—1.406(3) Å) appeared to be shorter than Ccarbonyl—Cethylene 
(1.435(2)—1.430(3) Å). In compound A06, the Ccarbonyl—Cethylene  (1.404(2) Å) and Cenol—Oenol 
(1.260(2) Å) were significantly shorter than in A01 and A02. This observation reveals electron 
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delocalization between a carbonyl group of the DETBA ring and the enol moiety, which is unique to 
A06.  
Table 3 Selected bond parameters observed in A01, A02, A06, A17, and A18. 
Bond parameter/Å A01 A02 A06 A17 A18 
















a (A01) C6—O2; (A02) C4—O2; (A06) C2—O6; (A17) C10—O2, C19—O4; (A18) C10—O1 
b (A01) C6—C7; (A02) C4—C5; (A06) C6—C7; (A17) C10—C8, C19—C18; (A18) C10—C9 
c (A01) C7—C8; (A02) C5—C3; (A06) C7—C9; (A17) C8—C7, C18—C17; (A18) C9—C8 
d (A01) C9—O3; (A02) C3—O3; (A06) C9—O3; (A17) C7—N1, C17—N4; (A18) C8—N3 
 
Hydrogen bonding patterns in the crystal packing of A01, A02, A06, A13, A17, and A18 are shown in 
Figure 2, while the hydrogen bond parameters are listed in Table 4. Intramolecular O—H…O hydrogen 
bonds with graph-set notation 𝑅2
2(6) were observed in enol derivatives A01, A02 and A06. Non-
classical, intermolecular C—H…S hydrogen bonds linked neighboring molecules to form chains that a 
one-dimensional supramolecular structure that extended along the crystallographic c axis. In A02, 
intermolecular C—H…O hydrogen bonds joined adjacent molecules to form a two dimensional, 
honeycomb-like supramolecular network extending along the crystallographic ab axis. The N—H…S 
hydrogen bonds sewed together neighboring molecules of A06 to form chains that extended along the 
crystallographic b axis. These chains were further joined via C—H…O hydrogen bonds along the 
crystallographic a axis to form a two-dimensional corrugated sheet-like supramolecular structure. A 
combination of intermolecular N—H…O and C—H…O hydrogen bonds (A17), formed six-membered 
rings with graphset notation 𝑅2
1(6) and resulted in a single-stranded helical supramolecular structure 
that elongated along the crystallographic b axis. On the other hand, N—H…O hydrongen bonds linked 
neighboring molecules to form chains that extended along the crystallographic b axis. Then C—H…O 
hydrogen bonds joined the chain along the crystallographic a anxis to form a two-dimensional, sheet-
like supramolecular architecture.  
3.3. Theoretical calculations 
A density functional theory (DFT) geometry optimization with the Gaussian09 program package (Frisch 
et al., 2009) employing the B3LYP (Becke three parameters Lee–Yang–Parr exchange-correlation 
functional, which combines the hybrid exchange functional of Becke (Becke, 1988) with the gradient-
correlation functional of Lee, Yang and Parr (Lee et al., 1988)) using 6-311G++(d,p) basis set was 
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performed in gas phase. No solvent corrections were made with these calculations as gas phase 
calculations frequently correspond quite well with crystal structures (Honarparvar et al., 2013). Starting 
geometries for A01, A04, A13, A17, and A18 were taken from X-ray refined data. The optimized 
geometry results in the free molecule state were compared to those in the crystalline state. No negative 
vibrational modes were obtained. The DFT calculated structure and geometric parameters (bond lengths 
and bond angles) were in agreement with each other. All optimized structures had a C1 point group.  
 The optimized geometry of A01 indicates the electron delocalization between atoms C16-C17-
C19-O28. The bond length between C19-O28 was 1.31 Å which is slightly higher than that of the 
carbonyl (C=O) (usually 1.22 Å), and H3-O3 formed a strong intra-molecular hydrogen bond with O2. 
However, A04, with a similar structure, showed delocalization of electrons in the TBA ring unlike that 
found in A01 but also the presence of strong intra-molecular hydrogen bonding. A13 showed the 
presence of two intra-molecular hydrogen bonds caused by the presence of a thioamide bond. A17 and 
A18 showed the presence of inter-molecular hydrogen bonding, in addition to intra-molecular hydrogen 
bonding. 
3.3.1. Frontier Orbital Energy Analysis and Molecular Total Energies 
Molecular Total Energy and Frontier Orbital energy levels were calculated using DFT (Table 5), as 
discussed previously by our group (Sharma et al., 2017). 
Table 4 Total energy and frontier orbital energy [B3LYP/6-311++G(d,p)] for A01.  
-- DFT (keto form) DFT (enol form) 
Etotala -1123.12965976 -1123.15077113 
EHOMO -0.24121 -0.23291 
ELUMO -0.09332 -0.09290 
ΔEb 0.14789 0.14001 
a 1 Hartree = 4.35974417 x 10-18 J = 27.2113845 eV; b ΔE = ELUMO - EHOMO.   
The crystal structure of A01 (enol form) was used for DFT calculations. The energy gap between 
HOMO and LUMO was calculated by the B3LYP method using the 6-311G++(d,p) basis set. The title 
compound (in enol form) showed an energy gap (ΔE = 0.14001 Hartree = 3.78 eV) for HOMO  
LUMO (Figure 4). This energy gap affords the theoretical absorption at max = 326 nm. The keto form 
was optimized using GaussView05 (Dennington et al., 2009), and the results were compared with those 
of the enol form (Table 4). The keto form showed an energy gap (ΔE = 0.14789 Hartree = 3.99 eV; max 
= 308 nm) for HOMO  LUMO that was higher than that of enol form.  HOMO and LUMO are 
important factors that affect bioactivity, chemical reactivity and electron affinity and ionization 
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potential (Clare, 1994, 1995, Zhang & Musgrave, 2007). Thus, the study of the frontier orbital energy 
can provide useful information about the biological and chemical reaction mechanism. 
 
Figure 4 Frontier molecular orbitals of the title compound [B3LYP/6-311++G(d,p)]. 
3.4. Transition State Calculations 
A transition state is broadly considered as the first order saddle point on the Potential Energy Surface 
(PES) of a molecular system. The vibrational spectrum of a transition state is characterized by one 
imaginary frequency (implying a negative force constant), which means that in one direction in nuclear 
configuration space the energy has a maximum, while in all other orthogonal directions the energy is a 
minimum (Lewars, 2003). In order to verify, A01 (keto form) was optimized using Gaussian09, 
followed by frequency calculations at the same computational level as that used for the enol form (A01). 
The energies calculated are listed in Table 6 and shown schematically in Figure 5. 
Table 5 Calculated reaction profile using DFT [B3LYP/6-311++G(d,p)]. 
-- 
Relative Energies (kcal/mol) 
Keto form 0 
Transition State 43.51 
Enol form -11.54 
 
Acta Crystallographica Section C research papers 
47 
 
The calculated energy confirms that the reaction (Figure 5) is more favorable in a forward direction, 
i.e the enol form. In order to convert the keto form to the enol, an energy barrier of 55.05 kcal/mol 
needs to be overcome (Table 6); this value is much higher than the inherent energy limit of 15-20 
kcal/mol at room temperature (Kruger, 2002, Singh et al., 2012).  
 
Figure 5 Transition state for a keto-enol form of A01. 
The theoretical results thus suggest that if the product (enol) forms, it will not interconvert at room 
temperature. This notion was also confirmed by the NMR spectra (only the enol form was observed). 
A similar observation was made for all similar derivatives. 
Conclusion 
 In conclusion, we have demonstrated the successful characterization of synthesized TBA 
derivatives by various spectroscopic techniques. The UV spectroscopy explained the absorptivity for 
the TBA derivatives at different wavelengths depending upon the structure. The max for the TBA 
derivatives did not reveal any significant shift upon comparison with a change of solvent. The absolute 
configuration for six derivatives was confirmed by single ray X-ray crystallography which indicates the 
formation of intramolecular H-bonding in all cases (A01, A02, A06, A13, A17, and A18) and also 
intermolecular H-bonding for A17. In A13 presence of two intramolecular bonding was observed. The 
acylation with simple carboxylic derivatives afforded the enamine, as shown by 1H-NMR and X-ray 
crystallography. The stabilization of enol over keto form was confirmed using Gaussian09 program 
package. To convert the keto form to the enol, an energy barrier of 55.05 kcal/mol needs to be overcome 
as confirmed by transition state calculations. These studies provide an insight into the field of material 
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science since TBA derivatives possess good NLO properties and corrosion inhibition properties. These 
results also support the application of TBA derivatives in designing engineering material due to their 
property of possessing both hydrogen bond donors and acceptors. 
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In conclusion, a series of thiobarbituric acid derivatives (A01 to A20) were successful synthesized, 
using different techniques this include substitution at position “N” of structure with symmetrical 
substituents (A14, A15, and A16), and substitution at C-5 position this include acylation (A01, 
A02, A03, A04, A05, A06, and A07); Schiff base (A08 and A09); Knoevenagel condensation 
(A10, A11 and A12); Thioamide (A13) and enamine formation ( A17, A18, A19 and A20) . The 
antimicrobial test was performed against selected bacteria Gram +ve (S.aureus and B.subtilus) and 
Gram-ve (E. coli and P. aeruginosa) the results showed that the N-alkylated TBA derivatives and 
the acyl TBA derivatives have higher activity than the aromatic TBA derivatives ones; the TBA 
derivatives with the amino acid result showed that TBA derivatives with the Phe amino acid have 
higher activity than TBA derivatives with Val amino acid. In the case of cytoxicity, they are non-
toxicity for the active TBA derivatives. (Chapter 2) 
The characterization of TBA derivatives was successfully characterize with various spectroscopic 
techniques such as NMR, UV, IR, and X-ray crystallography. Here UV spectroscopy was used to 
identify the absorptivity of TBA derivatives at different wavelength since they are known non-
aromatic compounds, the maximum wavelength of all derivatives was found in the range of 322 - 
285 nm respectively. The crystal structures of six TBA derivatives (A01, A02, A06, A13, A17, 
and A18) were successfully evaluated and the configuration was confirmed by X-ray 
crystallography which indicates the formation of intramolecular H-bonding in all cases (A01, A02, 
A06, A13, A17, and A18) and also intermolecular H-bonding for A17. In A13 presence of two 
intramolecular bonding was observed. The results of these TBA derivatives open up the possibility 
to explore more and construct new antibacterial agent using TBA moieties scaffolds, and their 
properties of possessing both hydrogen bond donors and acceptors put them in the position of 







Supporting Information   
In the CD, The characterization data of all synthesized TBA derivatives are attached, 
This include: 
- High-Performance Liquid Chromatography (HPLC) 
- High-Resolution Mass Spectrometry (HRMS) 
- Proton Nuclear Magnetic Resonance spectroscopy (1H NMR) 
- Carbon Nuclear Magnetic Resonance spectroscopy (13C NMR) 
- Infrared spectroscopy (IR)  
